Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, a B cell depleting antibody: A multicentre, open-label, prospective clinical trial with single treatment arm.

Trial Profile

Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, a B cell depleting antibody: A multicentre, open-label, prospective clinical trial with single treatment arm.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Methylprednisolone; Rituximab
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Pharmacodynamics
  • Acronyms RituxRABone
  • Most Recent Events

    • 31 Jul 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 11 Jun 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top